Signaling Pathway Map

Research Area

  • Inhibitory Selectivity
  • Solubility
Catalog No. Product Name Solubility(25°C)
Water DMSO Alcohol
S1009 Dactolisib (BEZ235, NVP-BEZ235) <1 mg/mL 0.01 mg/mL <1 mg/mL
S1092 KU-55933 (ATM Kinase Inhibitor) <1 mg/mL 33 mg/mL <1 mg/mL
S1570 KU-60019 <1 mg/mL 18 mg/mL <1 mg/mL
S8007 VE-821 <1 mg/mL 74 mg/mL <1 mg/mL
S2758 Wortmannin <1 mg/mL 85 mg/mL <1 mg/mL
S8666 BAY 1895344 (BAY-1895344) 82 mg/mL 82 mg/mL 82 mg/mL
S2817 Torin 2 <1 mg/mL 20 mg/mL <1 mg/mL
S2245 CP-466722 <1 mg/mL 0.28 mg/mL <1 mg/mL
S7102 VE-822 <1 mg/mL 36 mg/mL <1 mg/mL
S4157 Chloroquine Phosphate 100 mg/mL <1 mg/mL <1 mg/mL
S8050 ETP-46464 <1 mg/mL 6 mg/mL <1 mg/mL
S7136 CGK 733 <1 mg/mL 100 mg/mL <1 mg/mL
S7050 AZ20 <1 mg/mL 83 mg/mL 3 mg/mL
S7693 AZD6738 <1 mg/mL 82 mg/mL 41 mg/mL
S3600 Schisandrin B (Sch B) <1 mg/mL 80 mg/mL 10 mg/mL
S8096 Mirin <1 mg/mL 44 mg/mL <1 mg/mL
S8375 AZD0156 <1 mg/mL 5 mg/mL 2 mg/mL

Isoform-specific Inhibitors

Catalog No. Information Product Use Citations Product Validations

Dactolisib (BEZ235, NVP-BEZ235)

Dactolisib (BEZ235, NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3TopBP1-ER cell.


KU-55933 (ATM Kinase Inhibitor)

KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor with IC50/Ki of 12.9 nM/2.2 nM in cell-free assays, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.



KU-60019 is an improved analogue of KU-55933, with IC50 of 6.3 nM for ATM in cell-free assays, 270- and 1600-fold more selective for ATM than DNA-PK and ATR,and is a highly effective radiosensitizer.



VE-821 is a potent and selective ATP competitive inhibitor of ATR with Ki/IC50 of 13 nM/26 nM in cell-free assays, shows inhibition of H2AX phosphorylation, minimal activity against PIKKs ATM, DNA-PK, mTOR and PI3Kγ.



Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.


BAY 1895344 (BAY-1895344)

BAY 1895344 is a potent, highly selective and orally available ATR inhibitor with an IC50 of 7 nM.


Torin 2

Torin 2 is a potent and selective mTOR inhibitor with IC50 of 0.25 nM in p53−/− MEFs cell line; 800-fold greater selectivity for mTOR than PI3K and improved pharmacokinetic properties. Inhibition of ATM/ATR/DNA-PK with EC50 of 28 nM/35 nM/118 nM,in PC3 cell lines respectively.



CP-466722 is a potent and reversible ATM inhibitor, does not affect ATR and inhibits PI3K or PIKK family members in cells.



VE-822 is an ATR inhibitor with IC50 of 19 nM in HT29 cells.


Chloroquine Phosphate

Chloroquine phosphate is a 4-aminoquinoline anti-malarial and anti-rheumatoid agent, also acting as an ATM activator.



ETP-46464 is a potent and selective inhibitor of ATR with IC50 of 25 nM.


CGK 733

CGK 733 is a potent and selective inhibitor of ATM/ATR with IC50 of ~200 nM.



AZ20 is a novel potent and selective inhibitor of ATR kinase with IC50 of 5 nM in a cell-free assay, 8-fold selectivity over mTOR.



AZD6738 is an orally active, and selective ATR kinase inhibitor with IC50 of 1 nM. Phase 1/2.


Schisandrin B (Sch B)

Schisandrin B is the most abundant dibenzocyclooctadiene lignan present in the traditional Chinese medicinal herb Schisandra chinensis (Turcz.) Baill. It is a kind of ATR and P-gp inhibitor with high safety.



Mirin is a potent Mre11–Rad50–Nbs1 (MRN) complex inhibitor, and inhibits Mre11-associated exonuclease activity.



AZD0156 is a potent and selective inhibitors of ATM kinase, with potential chemo-/radio-sensitizing and antineoplastic activities.

Tags: ATM inhibition | ATR inhibition | ATM kinase activation | ATM kinase assay | ATM protein kinase | ATM signaling pathway | ATM inhibitor drugs | ATM tumor | ATM phosphorylation | ATM targets | ATM cancer | ATM activity | ATM inhibitor clinical trial | ATM inhibitor review